| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 08/12/2004 | WO2004066946A2 Method for evaluating the efficacy of certain cancer treatments |
| 08/12/2004 | WO2004066933A2 Compositions and methods for treating cancer using igsf9 and liv-1 |
| 08/12/2004 | WO2004066908A2 Composition containing cationic lipids and a polynucleotide or a polypeptide and method for the targeted delivery of active substances |
| 08/12/2004 | WO2004054969A3 Sacromastigophoric therapeutic agent delivery system |
| 08/12/2004 | WO2004053061A8 Methods of therapy and diagnosis using targeting of cells that express lax |
| 08/12/2004 | WO2004050859A3 Homologous recombination in multipotent adult progenitor cells |
| 08/12/2004 | WO2004050680A3 Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses |
| 08/12/2004 | WO2004048582A3 Recombinant poxvirus comprising at least two cowpox ati promoters |
| 08/12/2004 | WO2004047734A3 Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| 08/12/2004 | WO2004032880A3 Method for inhibiting angiogenesis with ship-1 inhibitors |
| 08/12/2004 | WO2004032860A3 Hiv vaccine formulations |
| 08/12/2004 | WO2004020592A3 Retroductal salivary gland genetic vaccination |
| 08/12/2004 | WO2004009024A3 Modulation of protein kinase c-iota expression |
| 08/12/2004 | WO2004007678A3 Codon optimized synthetic plasmids |
| 08/12/2004 | WO2004007531A3 Activated checkpoint therapy and methods of use thereof |
| 08/12/2004 | WO2003079977A3 Novel compositions and methods in cancer associated with altered expression of mcm3ap |
| 08/12/2004 | WO2003037060A3 Compositions and methods for wt1 specific immunotherapy |
| 08/12/2004 | WO2003032913A3 Methods and compositions for targeting proteins across the blood brain barrier |
| 08/12/2004 | WO2003029293A3 Modulators of notch ic protease activity for use in immunotherapy |
| 08/12/2004 | WO2002090504A3 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| 08/12/2004 | US20040158045 Nucleotide sequences coding tumor necrosis factor binding proteins for prevention and treatment of bone disorders |
| 08/12/2004 | US20040157792 antigen presenting cells (APCs) that express apoptosis inducing ligands and processed viral vector antigens are utilized to directly induce apoptosis of T-cells expressing the ligand receptor resulting in vector-specific T-cell tolerance |
| 08/12/2004 | US20040157791 Systemic immune activation method using nucleic acid-lipid complexes |
| 08/12/2004 | US20040157790 introducing the polynucleotide in a solution into a vessel of the heart, increasing the permeability of the vessel with hydrostatic pressure to the polynucleotide and delivering the polynucleotide to the cardiac tissue cell |
| 08/12/2004 | US20040157775 Effector proteins of rapamycin |
| 08/12/2004 | US20040157332 Using prokaryotic recombinase to initiate site specific insertion/deletion of extrachromosomal segments of DNA into eukaryotic genomes; gene therapy |
| 08/12/2004 | US20040157329 Transfecting chondrocytes and other mesenchymal cells with vectors comprising genes capable of stimulating chondrogenesis, osteogenesis, growth, repair, regeneration and/or restoration of the cellular matrix |
| 08/12/2004 | US20040157327 Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto |
| 08/12/2004 | US20040157308 Alpha-galactosidase as food-grade genetic marker |
| 08/12/2004 | US20040157307 for treating a patient with cancer comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient; genetic engineering; drug delivery; kits |
| 08/12/2004 | US20040157299 by transducing the tumor cells with a herpes simplex virus amplicon containing the gene for an immunomodulating protein; for multi-transduced cells for multi-targeted therapy; genetic engineering |
| 08/12/2004 | US20040157296 Canine and feline B7-2 proteins, compositions and uses thereof |
| 08/12/2004 | US20040157292 Sperm-specific cation channel, CatSper1, and uses therefor |
| 08/12/2004 | US20040157282 Regulation of human dual specificity protein phosphatase 7-like protein |
| 08/12/2004 | US20040157261 Kv10.1, a novel voltage-gated potassium channel from human brain |
| 08/12/2004 | US20040157259 Novel human ion channel protein and polynucleotides encoding the same |
| 08/12/2004 | US20040157258 Isolated nucleic acid comprising polynucleotide of given sequence; screening methods for identifying binding partners of polypeptides; use in diagnosis and treatment |
| 08/12/2004 | US20040157250 Contacting a test compound with an expression system comprising an ABCA1 polynucleotide and detecting a change; use in treating coronary artery disease |
| 08/12/2004 | US20040157246 Purified protein encoded by a nucleic acid hybridizable to a DNA of given sequence; use in diagnosis, prognosis and screening for a disposition to cardiovascular disorders |
| 08/12/2004 | US20040157239 Endonuclease capable of cleaving DNA from divalent cations, which retains its activity in acidic to neutral pH range, and is not inhibited by G-actin; treatment of cystic fibrosis |
| 08/12/2004 | US20040157232 for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases |
| 08/12/2004 | US20040157222 for drug screening anti-cancer, asthma, obesity, diabetes, central nervous system and cardiovascular disorder drugs; genetic engineering; kits |
| 08/12/2004 | US20040156909 especially amphiphilic cationic or anionic vinyl ether polymers (e.g., copolymerized with maleic anhydride) electrostatically or covalently attached to the polynucleotide |
| 08/12/2004 | US20040156904 matrix of PEG-g-chitosan and water insoluble polylactic acid, poly-lactide glycolide, polycaprolactones, EVA, or polyanhydridie used as a delivery vehicle for pharmaceuticals and biomedical materials. |
| 08/12/2004 | US20040156848 Therapeutic uses of factors which inhibit or neutralize MIF activity |
| 08/12/2004 | US20040156838 inducing cytotoxic T-lymphocytes that will specifically down-regulate B-cells producing autologous IgE, notably by means of nucleic acid vaccination or live vaccination; inducing a combined antibody and CTK response specific for IgE |
| 08/12/2004 | US20040156833 Devices and methods for implanting transduced cells |
| 08/12/2004 | US20040156830 Vector and pharmaceutical composition containing cell death inducing gene |
| 08/12/2004 | US20040156828 Adeno-associated virus mediated B7.1 vaccination synergizes with angiostatin to eradicate disseminated liver metastatic cancers |
| 08/12/2004 | US20040156827 Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars |
| 08/12/2004 | US20040156826 Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| 08/12/2004 | US20040156825 Short immunomodulatory oligonucleotides |
| 08/12/2004 | CA2514646A1 Factor viii polypeptide |
| 08/12/2004 | CA2514517A1 Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
| 08/12/2004 | CA2514417A1 Custom-made meganuclease and use thereof |
| 08/12/2004 | CA2514179A1 Modified trafficking patterns for arrestin and g-protein-coupled receptors via arrestin-ubiquitin chimera |
| 08/12/2004 | CA2514062A1 Compositions and methods for treating cancer using igsf9 and liv-1 |
| 08/12/2004 | CA2513769A1 Method for evaluating the efficacy of certain cancer treatments |
| 08/12/2004 | CA2513398A1 Antisense oligonucleotides that inhibit expression of hif-1 |
| 08/11/2004 | EP1445322A1 Packaging systems for human recombinant adenovirus to be used in gene therapy |
| 08/11/2004 | EP1445315A1 Human and mammalian stem cell-derived neuronal survival polypeptides |
| 08/11/2004 | EP1444999A1 Low pressure gas accelerated gene gun |
| 08/11/2004 | EP1444986A1 Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
| 08/11/2004 | EP1444890A1 RS1 deficient transgenic animal and uses thereof |
| 08/11/2004 | EP1444353A2 Herpes simplex virus amplicon vector targeting system and method of using same |
| 08/11/2004 | EP1444347A2 METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs |
| 08/11/2004 | EP1444346A2 Sirna knockout assay method and constructs |
| 08/11/2004 | EP1444335A2 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| 08/11/2004 | EP1444262A2 Growth hormone variations in humans and their uses |
| 08/11/2004 | EP1444256A2 Enzyme-deficient c3 botulinum protein species and their use to promote neuronal growth and neuronal regeneration |
| 08/11/2004 | EP1443971A2 METHOD OF USING 18080, A HUMAN SERINE CARBOXYPEPTIDASE FAMILY MEMBER |
| 08/11/2004 | EP1443970A2 Promoters exhibiting endothelial cell specificity and methods of using same |
| 08/11/2004 | EP1443955A1 Treatment of central nervous system disorders by use of pdgf or vegf |
| 08/11/2004 | EP1443913A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 08/11/2004 | EP1443905A2 Compositions for oral gene therapy and methods of using same |
| 08/11/2004 | EP1443818A2 Novel secreted proteins and their uses |
| 08/11/2004 | EP1003776B1 Screening method using FREAC-11 transcription factor |
| 08/11/2004 | EP0804453A4 Method for detection and treatment of breast cancer |
| 08/11/2004 | EP0779922B1 Modified human c3 proteins |
| 08/11/2004 | EP0749472B1 Extracorporeal cell culture and transplantation kits |
| 08/11/2004 | EP0730648B1 HUMAN MUTATOR GENE hMSH2 AND HEREDITARY NON POLYPOSIS COLORECTAL CANCER |
| 08/11/2004 | EP0604560B1 Human cyclin e |
| 08/11/2004 | CN1520318A Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 08/11/2004 | CN1520304A Xenogenic oligo of or/and polyribonucleotides as agents for treatment of malignant twnours |
| 08/11/2004 | CN1520303A Turnor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors |
| 08/11/2004 | CN1520259A Method to treat hemophilia by hepatic gene transfer of factor VIII/IX with vesicle vector |
| 08/11/2004 | CN1519325A Shuttle plasmid of adenovirus and its constructing method |
| 08/11/2004 | CN1519032A Plasmid for gene therapy of cardiac muscle |
| 08/11/2004 | CN1161378C Antitumour polypeptide and gene therapy vector composition |
| 08/11/2004 | CN1161110C Oral delayed immediate release formulation and method of preparation therefor |
| 08/10/2004 | US6774227 Reating disorders related to cellular overproliferation comprising neutralizing the production or activity of macrophage migration inhibitory factor (mif) |
| 08/10/2004 | US6774217 Use of fragile histidine triad gene (fhit) genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states associated with cell overproliferation |
| 08/10/2004 | US6774216 Antibody for use in diagnosis and treatment of immunological, inflammatory and nervous system disorders |
| 08/10/2004 | US6774120 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 08/10/2004 | US6774119 Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells |
| 08/10/2004 | US6774118 Therapeutic use of CIS-element decoys in vivo |
| 08/10/2004 | US6774105 Methods of using latent TGF-β binding proteins |
| 08/10/2004 | US6773920 Delivery of functional protein sequences by translocating polypeptides |
| 08/10/2004 | US6773909 Concentration and lysis of adenovirus-infected cells in a single unit operation |
| 08/10/2004 | US6773881 By modulating vascular endothelial growth factor (vegf) |